| Document |
Document Title |
|
WO/2023/178327A1 |
Described are peptides comprising a membrane translocation domain having one or more cell penetrating peptide motifs, where at least one cell penetrating peptide motif is from 3 to 10 amino acid residues in length and has at least three ...
|
|
WO/2023/163227A1 |
The present invention provides a linker, a linker/payload, an antibody-drug conjugate, and an antitumor drug that are novel. Specifically, the present invention provides an antibody-drug conjugate that is represented by general formula (...
|
|
WO/2023/163234A1 |
The present invention provides: a method for improving the stability of an antibody-drug conjugate in vivo; and a conjugate precursor for producing a stabilized antibody-drug conjugate. More specifically, the present invention provides: ...
|
|
WO/2023/127503A1 |
This invention relates to a method for changing hydrogel volume, the method comprising: a step A for bringing an ionic polymer into contact with a hydrogel, which has a site having decomposition activity for the ionic polymer and a cross...
|
|
WO/2023/100158A1 |
The application relates to fluorescence-quenched substrates of Formula (I) for an acid β-glucosidase (GCase) and their use in a method for determining GCase activity in a cell or tissue, a method for localizing GCase activity within a c...
|
|
WO/2022/221144A9 |
Embodiments of the claimed invention are directed to synthetic peptides comprising an amino acid sequence of X1X2VX3NLRGDLQVLX4QKVCX5T (SEQ ID NO:18), wherein at least one of X1 and X2 is a cysteine, and wherein one or more of X3, X4, an...
|
|
WO/2023/068327A1 |
The present invention addresses the problem of: providing a method for reliably chemogenetically controlling the activity of a protein, and providing a protein used in this method. Specifically, the present invention is a plurality of pr...
|
|
WO/2023/058527A1 |
A compound represented by formula (1) [in formula (1): Xaa, Xaa1, Xaa2 and Xaa3 independently represent an arbitrary amino acid residue; n represents an integer of 1-20; R is nil or represents a straight-chain or branched sugar chain con...
|
|
WO/2023/042875A1 |
The present invention addresses the problem of providing: a gel formation kit which can be used for the production of a non-human animal and enables the formation of a tumor with high efficiency within a short period of time in the produ...
|
|
WO/2023/032994A1 |
Provided are a compound and a labeled biomaterial, the compound having a phosphor part and a structure represented by general formula (I). In general formula (I), A1 denotes a structure represented by general formula (a1), A2 denotes a s...
|
|
WO/2023/032996A1 |
A compound which has at least two phosphor parts and a structure represented by general formula (I), and a labeled biomaterial. In the formula, X1 to X3 represent -O-, -S-, >NR1 or >CR2R3. R1 to R3 represent a hydrogen atom or a substi...
|
|
WO/2023/032995A1 |
This compound has two or more fluorescent portions that are equivalent in terms of light-absorbing characteristics. In the compound, the fluorescent portions adjacent to each other are linked via a group having a structure represented by...
|
|
WO/2023/008321A1 |
Provided is a method for identifying an unknown splicing peptide derived from a known parent peptide included in a biological sample, wherein the method includes: (1) a first step for obtaining mass spectrometry data pertaining to peptid...
|
|
WO/2023/277186A1 |
Provided is a means that makes it possible to simultaneously and accurately analyze a target peptide, a component derived from a carrier for liquid phase peptide synthesis, and the like. Provided is a method for simultaneously analyzin...
|
|
WO/2023/276967A1 |
Provided is a novel polymer composition exhibiting osmoregulatory activity. Provided particularly is an osmolyte which can inhibit protein alteration, etc. in lower concentrations. This osmoregulator is characterized by comprising a po...
|
|
WO/2022/234851A1 |
It has been discovered that a large binding selectivity for the RAS(G12D) mutant is possessed by a binding molecule that has the following characteristic features: (i) direct interaction with the Asp12 in the RAS(G12D) mutant and (ii) in...
|
|
WO/2022/218331A1 |
Provided herein are a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.
|
|
WO/2022/217490A1 |
A method for preparing a collagen peptide. The method comprises the following steps: pre-treating fish skin and fish meat, then adding 0.5 monl/L of a glacial acetic acid solution and pepsin with a mass fraction of 3%, stirring the mixtu...
|
|
WO/2022/194238A1 |
There is provided a conjugate formed between an anaesthetic compound and a peptide component of the amino acid sequence: W-Lys-X 1-Ser-U-X 2-Y wherein: W, X 1, U, X 2 and Y are as defined in the description, as well as regioisomers, ster...
|
|
WO/2022/193185A1 |
Provided are a conjugate formed between an anaesthetic compound and a peptide component of the amino acid sequence:W-Lys-X1-Ser-U-X2-Y, wherein:W, X1, U, X2 and Y are as defined in the description, as well as regioisomers, stereoisomers,...
|
|
WO/2022/149584A1 |
The present invention provides a peptide having a fluoroalkyl group as a side chain. The present invention pertains to a peptide in which two or more amino acids are peptide-bonded, wherein at least one of the amino acid residues constit...
|
|
WO/2022/109163A1 |
Controlled release biodegrading microcapsules comprising polypeptide chains.
|
|
WO/2022/097500A1 |
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
|
|
WO/2022/065173A1 |
Provided are: a membrane-permeable molecule which has a structure represented by general formula (i) and forms a salt with an acid having a pKa value greater than -8.0 and less than 4.7; and a method for improving the membrane permeabili...
|
|
WO/2022/065172A1 |
A cell membrane-permeable molecule which has a structure represented by general formula (I) and which is in the form of a salt with an acid having a pKa value of lower than 4.7; and a method of improving the cell membrane permeability of...
|
|
WO/2022/054625A1 |
Provided is a complex containing a pyrrole-imidazole polyamide that recognizes a particular DNA sequence and binds thereto and containing peptide that contains 1-5 arginine residues.
|
|
WO/2021/235494A1 |
Provided is a medical agent that exerts preventative and therapeutic effects against viral infections, by inhibiting proteases of viral origin on the basis of the effects of various physiological activities of an active sulfur compound p...
|
|
WO/2021/231920A1 |
The present disclosure relates to methods of writing data in nucleic acid chains and methods of reading data written in nucleic acid chains. The present disclosure also relates to a kit for writing and reading data in nucleic acid chains.
|
|
WO/2021/156331A2 |
The invention relates to use of ionic polymers (IP) consisting of anions and a polymeric backbone containing cations, in hydrolyzing proteins and protein-containing feedstock to produce protein hydrolysates.
|
|
WO/2021/155354A1 |
A method for the prevention, treatment, or amelioration of a medical disease or condition associated with inflammation caused by glutamate excitotoxicity comprising administering to a patient a peptide that binds to or interferes with th...
|
|
WO/2021/136475A1 |
A linker molecule for targeting molecule-drug conjugate, has the structure of formula (I): A1p-D1q-Y-Lk-W-A2q-D2p (I). A conjugate has the structure of formula (III): A-((compound of formula (I))-PL t) z (III). The conjugate can be used ...
|
|
WO/2021/108919A1 |
A method and system for generating a protein sequence is implemented using a computer-implemented neural network. An empty or partially filed sequence of node elements, representing amino acid positions of the protein sequence, and an ed...
|
|
WO/2021/106706A1 |
The present invention improves the accuracy of searching for an amino acid sequence of interest. An information processing device (amino acid sequence searching device) 1 is provided with: a storage unit 17 that stores a trained model fo...
|
|
WO/2021/058660A1 |
The present invention is directed to an anti-adsorption solution for the analysis of peptides. Also a process for the preparation of such an anti-adsorption solution and the use of said anti-adsorption solution are described.
|
|
WO/2021/055696A1 |
Single-module nonribosomal peptide synthetases (NRPSs) and NRPS-like enzymes activate and transform carboxylic acids in both primary and secondary metabolism; and are of great interest due to their biocatalytic potentials. The single-mod...
|
|
WO/2021/047648A1 |
Provided is a peptide compound comprising the amino acid sequence: G-W-Lys-X1-Ser-U-X2-Y-Z-Q wherein: G represents an optional N-terminal a 3, 4-dihydrocinnamic acid group; W represents Ala or Ser, or is absent; U represents Tyr, DOPA or...
|
|
WO/2021/010316A1 |
The present invention addresses the problem of providing an N-substituted amino acid-containing peptide and a method for producing a protein binding factor using the peptide. More specifically, the present invention pertains to a peptide...
|
|
WO/2020/262555A1 |
A side effect reducing agent for a nucleic acid drug that comprises an oligopeptide containing an oligopeptide domain, said oligopeptide domain consisting of 2-40 amino acids and including a structure W that has two or more specific cons...
|
|
WO/2020/226438A1 |
The present invention relates to a peptide for preventing or treating inflammatory bowel diseases. The peptide of the present invention exhibits excellent effects in preventing or treating inflammatory bowel diseases and thus can be extr...
|
|
WO/2020/213568A1 |
Disclosed is a method for producing a polymerized polypeptide aggregate, said method comprising a step for reacting a polypeptide, which has a tag on the N-terminal side and/or C-terminal side, with a polymerase to give a reaction liquid...
|
|
WO/2020/203626A1 |
The present invention provides a biologically-related substance to which a branched degradable polyethylene glycol derivative being decomposed in cells and being represented by formula (A) below is bound. (In the formula, each symbol is ...
|
|
WO/2020/195302A1 |
Provided is a linker molecule for producing a cell membrane-permeable ring-shaped peptide, the linker molecule having a cell membrane permeability-imparting group; and a ring-forming group which forms a peptide into a ring shape.
|
|
WO/2020/198644A1 |
The present disclosure is directed to physical mixtures of diblock copolypeptide hydrogel (DCH) systems. These systems exhibit mechanical strength and stiffness that are synergistically increased over the individual component DCHs, to gr...
|
|
WO/2020/158687A1 |
In the present invention, a method for producing a compound of formula I comprises a step for causing a compound of formula III to undergo a Pechmann condensation reaction with respect to a compound of formula II in the presence of an or...
|
|
WO/2020/125307A1 |
Disclosed is a method for constructing a Pseudomonas aeruginosa O11 serotype O antigen oligosaccharide using a D-glucose block, a L-fucosamine block and a D-fucosamine block, wherein the D-glucose block or the L-fucosamine block is conne...
|
|
WO/2020/112647A1 |
This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.
|
|
WO/2020/097188A1 |
Disclosed herein are compositions and methods for the identification of molecules capable of repressing NK-mediated killing of a target (donor) cell. The invention comprises the development and use of an assay to detect the effects of ta...
|
|
WO/2020/077136A1 |
Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, w...
|
|
WO/2020/058889A1 |
The present patent application relates to the use of an innovative amino acid derivative of glucosamine having the Formula 1 of the general structure which follows, or of a pharmaceutical composition which contains it as a single active ...
|
|
WO/2020/052677A1 |
There is provided a peptide-containing compound that comprises a peptide component which is an amino acid sequence of from 2 to 45 amino acids, which peptide component is covalently bonded to one or more compounds of the formula (I), whe...
|
